Avalo Therapeutics (AVTX) has raised $472 million, ensuring funding through 2029 to support its registrational-stage biotech development. The company’s lead drug, abdakibart, showed strong Phase II results for treating hidradenitis suppurativa, with significant efficacy and a clean safety profile in both biologic-experienced and naive patients. This financial strength reduces near-term dilution risk and boosts Avalo's leverage for upcoming Phase 3 trials and further pipeline development, including AVTX-010, which aims to improve dosing intervals and extend intellectual property protection. The company’s strategy targets a high-risk, differentiated market opportunity in hidradenitis suppurativa treatment.
Anthropic, an AI company, is expected to go public with its IPO on November 19, 2026. However, analyst Daniel Sparks suggests that investors might be better off buying Amazon stock instead of Anthropic's IPO shares. This reflects skepticism about the...
Nekteck announced its Black Friday and Cyber Monday 2026 promotions featuring discounts on popular wellness devices like the Shiatsu Foot Massager, Neck and Back Massager, and Cordless Air Compression Leg Massager. These products, designed for everyd...
China Eastern Airlines signed 23 procurement contracts worth $540 million with international suppliers at the 9th China International Import Expo (CIIE) in Shanghai. The deals include aircraft engines, aviation materials, jet fuel, and catering suppl...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 international suppliers at the 9th China International Import Expo in Shanghai. The deals cover aviation engines, materials, jet fuel, and catering, including orders f...
China Eastern Airlines secured 23 purchase contracts worth $540 million with international suppliers at the 9th China International Import Expo in Shanghai. The deals include aircraft engines, aviation materials, and in-flight services, aiming to enh...
